Pediatric off-label use of recombinant factor VIIa

Pediatrics

Volumn 123, Issue 3, 2009, Pages 1066-1072

  Alten, Jeffrey A ^a,c   Benner, Kim ^b   Green, Kelsey ^b   Toole, Benjamin ^a   Tofil, Nancy M ^a   Winkler, Margaret K ^a  

^a University of Alabama at Birmingham and Children's Hospital   (United States)

^b SAMFORD UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Bleeding; Pediatrics; Recombinant factor viia; Thromboembolism; Transfusion

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ARTICLE; BLEEDING; CHILD; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHILIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; OFF LABEL DRUG USE; PRESCHOOL CHILD; PRIORITY JOURNAL; SEPSIS; SURVIVAL RATE; THROMBOSIS; ADOLESCENT; BLOOD; DOSE RESPONSE; DRUG APPROVAL; HOSPITAL; INFANT; INJURY; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; PREMEDICATION; PROTHROMBIN TIME;

ADOLESCENT; BLOOD LOSS, SURGICAL; CHILD; CHILD, PRESCHOOL; DISSEMINATED INTRAVASCULAR COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; FACTOR VIIA; FEMALE; HEMORRHAGE; HOSPITALS, PEDIATRIC; HUMANS; INFANT; MALE; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; PREMEDICATION; PROTHROMBIN TIME; RECOMBINANT PROTEINS; SURVIVAL RATE; WOUNDS AND INJURIES;

EID: 63149143387     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-1685     Document Type: Article

References (40)

1. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIIa. J Biotechnol. 2006;124(4): 747-757
2. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIla as adjunctive therapy for bleeding control in severely injures trauma patients: two randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59(1):8-15
3. Rizoli S, Nascimento B, Osman F, et al. Recombinant activated coagulation factor Vii and bleeding trauma patients. J Trauma. 2006;61(6):1419-1425
4. Warren O, Mandal K, Hadjianastassiou V, et al. Recombinant activated factor VII in cardiac surgery: A systematic review. Ann Thorac Surg. 2007;83(2):707-714
5. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIla for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double blind trial. Gastroenterology. 2004;127(4): 1123-1130
6. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352(8):777-785
7. Friederich PW, Henry CP, Messelink EJ et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomized trial. Lancet. 2003;361(9353): 210-205
8. Voils S. Pharmacologic interventions for the management of critical bleeding. Pharmacology. 2007;27:69S-84S
9. MacLaren R, Weber LA, Brake H, et al. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes. Transfusion. 2005;45(9): 1434-1442
10. O'Connell K, Wood J, Wise R, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;3:293-298
11. Pollack MM, Ruttiman UE, Getson PR. The Pediatric risk of mortality (PRISM) score. Crit Care Med. 1988;16(11): 1110-1116
12. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6(1):2-8
13. Mathew P. The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. Thromb Haemost. 2004;92(4):738-746
14. Reiter PD, Valuck RJ, Taylor RS. Evaluation of off-label recom-binant activated factor VII for multiple indications in children. Clin Appl Thromb Hemost. 2007;13(3):233-240
15. Agarwal HS, Bennett JE, Churchwell KB, et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg. 2007;84(1):161-169
16. Pettersson M, Fischler B, Petrini P, et al. Recombinant FVIIa in children with liver disease. Thromb Res. 2005;116(3):185-197
17. Brady K, Easley B, Tobias J. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage. Pediatr Anaesth. 2006;16(10):1042-1046
18. Tobias J, Groeper K, Berkenbosch J. Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric patients. South Med J. 2003;96(1): 12-16
19. Razon Y, Erez E, Vidne B, et al. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Pediatr Anaesth. 2005;15(3):235-240
20. Das P, Carcao M, Hitzler J. Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. Pediatr Blood Cancer. 2006;47(2):206-209
21. Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost. 2005;3(4):640-648
22. Vincent JL, Rossaint R, Ozier Y, et al. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding: a European perspective. Crit Care. 2006;10(4):R120
23. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant actor VIIa for treatment of severe bleeding: A systematic review. Crit Care Med. 2005;33(4):883-890
24. Stein DM, Dutton RP, O'Connor J, et al. Determinants of futility of administration of recombinant factor VIIa in trauma. J Trauma. 2005;59(3):609-615
25. Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. N Engl J Med. 2006;355(13): 1303-1305
26. Levi M. Disseminated intravascular coagulation. Crit Care Med. 2007;35(9):2191-2195
27. Chuansumrit A, Wangruangsatid S, Lektrakul Y, et al. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagul Fibrinolysis. 2005;16(8): 549-555
28. Biss TT, Hanley JP. Recombinant activated factor VII (rFVIIa/ NovoSeven) in intractable haemorrhage: use of a clinical scoring system to predict outcome. Vox Sang. 2006;90(1):45-52
29. Bowles KM, Park GR, Callaghan CJ, et al. Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage. Br J Anaesth. 2006;97(4)4:476-481
30. Clark AD, Gordon WC, Walker ID, et al. "Last-ditch" use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang. 2004;86(2):120-124
31. Johnson SJ, Ross MB, Moores KG. Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery. Am J Health Syst Pharm. 2007;64(17):1808-1812
32. Pihusch M, Bacigalupo A, Szer J, et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost. 2005;3(9):1935-1944
33. Ghorashian S, Hunt B. "Off-license" use of recombinant activated factor VII. Blood Rev. 2004;18(4):245-259
34. Raivio P, Suojaranta-Ylinen R, Kuitunen AH. Recombinant Factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg. 2005;80(1):66-71
35. Levy JH, Fingerhut A, Brott T, et al. Recombinant factorVIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion. 2006;46(6):919-933
36. Thomas GO, Dutton RP, Hemlock B, et al. Thromboembolic complications associated with factor VIIa administration. J Trauma. 2007;62(3):564-569
37. Khan ZH, Soltani AE, Rahmani P. Postoperative pulmonary thromboembolism possibly associated with recombinant activated factor VII infusion for the treatment of uncontrolled hemorrhage during vertebral instrumentation. J Anesth. 2007; 21(2):258-260
38. Libman RB, Lungu C, Kwiatkowski T. Multiple ischemic strokes associated with use of recombinant activated factor VII. Arch Neurol. 2007;64(6):879-881
39. Ekert H, Brizard C, Eyers R, et al. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis. 2006;17(5): 389-395
40. Veldman A, Josef J, Fischer D, et al. A prospective pilot study of prophylactic treatment of preterm neonates with recombi-nant activated factor VII during the first 72 hours of life. Pediatr Crit Care Med. 2006;7(1):34-39